Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Dayantha Fernando
Observed name:
D. Fernando
Institution:
University of California, Irvine
Observed institution:
University of California, Irvine
ORCID:
0000-0001-5649-1433
Observed ORCID:
0000-0001-5649-1433
OpenAlex ID:
A5011636511
Outcomes of Irreversible Electroporation for Treatment of Refractory Locally Advanced Pancreatic Cancer
2026
·
Ricardo Azevedo
, David Imagawa
, et al.
·
Journal of Vascular and Interventional Radiology
PDF
A phase 2, open-label single-arm, multi-center study of trans-arterial tirapazamine embolization (TATE) combined with nivolumab (nivo) in patients with advanced immunotherapy-refractory hepatocellular carcinoma (HCC).
2026
·
Nadine Abi-Jaoudeh
, Jennifer Brooke Valerin
, et al.
·
Journal of Clinical Oncology
Phase 2 study of cabozantinib (Cabo) combined with ipilimumab (Ipi)/nivolumab (Nivo) and transarterial chemoembolization (TACE) in patients with liver limited unresectable hepatocellular carcinoma (uHCC).
2026
·
Farshid Dayyani
, Jennifer Brooke Valerin
, et al.
·
Journal of Clinical Oncology
PDF
Overall Survival after Y-90 Selective Internal Radiotherapy of Liver Metastases in Oligometastatic Patients
2022
·
J. Yeakel
, J.V. Kuo
, et al.
·
International Journal of Radiation Oncology*Biology*Physics
Show more works
View as search
Works count:
4
Citation count:
H-index:
I10-index:
Year
Topic
Type